Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 615 participants.

Also called NCT01763827

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 615 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01763827
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Belgium, Canada, Denmark, France, South Africa, South Korea, Taiwan, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01763827. Randomized; quadruple masking; primary purpose treatment. Start 2013-01-21 (actual); primary completion 2013-10-10 (actual). Results posted on 2015-12-30.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2
Acronym
MENDEL-2
Condition
Hyperlipidemia
Intervention (Biological)
Evolocumab
Intervention (Drug)
Ezetimibe
Intervention (Biological)
Placebo to Evolocumab
Intervention (Other)
Placebo to Ezetimibe
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct01763827
Content hash
3d2582303ff3b26e30b4fc31d9e9fb3db7b8b8b7bf89f1657491959d48c03e18